Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Vazquez, Juan Carlos
- dc.contributor.author Antolin, Silvia
- dc.contributor.author Ruiz-Borrego, Manuel
- dc.contributor.author Servitja Tormo, Sonia
- dc.contributor.author Alba, Emilio
- dc.contributor.author Barnadas, Agustí
- dc.contributor.author Lluch, Ana
- dc.contributor.author Martín, Miguel
- dc.contributor.author Rodríguez-Lescure, Álvaro
- dc.contributor.author Solà, Ivan
- dc.contributor.author Bonfill, Xavier
- dc.contributor.author Urrutia, Gerard
- dc.contributor.author Sanchez-Rovira, Pedro
- dc.date.accessioned 2023-03-02T07:37:41Z
- dc.date.available 2023-03-02T07:37:41Z
- dc.date.issued 2022
- dc.description [AHEAD] Data de publicació electrónica: 22-11-2022
- dc.description.abstract Background: we aimed to determine the effect of dual anti-HER2 blockade compared to monotherapy on clinically important outcomes. Methods: we carried out a systematic review updated until July 2022. The outcomes included pathological complete response (pCR), clinical response, event-free survival, and overall survival. Results: we identified eleven randomized clinical trials (2836 patients). When comparing paclitaxel plus dual treatment versus paclitaxel plus trastuzumab or lapatinib, dual treatment was associated with a higher probability of achieving a pathological complete response (OR 2.88, 95% CI 2.02-4.10). Addition of a taxane to an anthracycline plus cyclophosphamide and fluorouracil, plus lapatinib or trastuzumab, showed that the dual treatment was better than lapatinib alone (OR 2.47, 95% CI 1.41-4.34), or trastuzumab alone (OR 1.89, 95% CI 1.13-3.16). Dual treatment may result in an increase in survival outcomes and tumour clinical response, although such benefits are not consistent for all the combinations studied. Conclusions: the use of dual blockade with combinations of trastuzumab and pertuzumab can be recommended for the neoadjuvant treatment of women with HER2-positive breast cancer. PROSPERO Registration number: CRD42018110273.
- dc.format.mimetype application/pdf
- dc.identifier.citation Vazquez JC, Antolin S, Ruiz-Borrego M, Servitja S, Alba E, Barnadas A, et al. Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis. Clin Transl Oncol. 2022 Nov 22. DOI: 10.1007/s12094-022-02998-2
- dc.identifier.doi http://dx.doi.org/10.1007/s12094-022-02998-2
- dc.identifier.issn 1699-048X
- dc.identifier.uri http://hdl.handle.net/10230/56011
- dc.language.iso eng
- dc.publisher Springer
- dc.rights This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s12094-022-02998-2
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.subject.keyword Breast cancer
- dc.subject.keyword Human epidermal growth factor receptor
- dc.subject.keyword Lapatinib
- dc.subject.keyword Neoadjuvant
- dc.subject.keyword Pathological complete response
- dc.subject.keyword Trastuzumab
- dc.title Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the treatment of women with non-metastatic HER2-positive breast cancer: a systematic review and meta-analysis
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/acceptedVersion